318 related articles for article (PubMed ID: 12682803)
1. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting drug concentrations and QT interval during thioridazine therapy.
Thanacoody RH; Daly AK; Reilly JG; Ferrier IN; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):555-65. PubMed ID: 17460606
[TBL] [Abstract][Full Text] [Related]
3. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
4. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
5. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
[TBL] [Abstract][Full Text] [Related]
6. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
LLerena A; Berecz R; de la Rubia A; Dorado P
J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
[TBL] [Abstract][Full Text] [Related]
7. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
[TBL] [Abstract][Full Text] [Related]
9. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.
Llerena A; Berecz R; Dorado P; de la Rubia A
J Psychopharmacol; 2004 Jun; 18(2):189-93. PubMed ID: 15260906
[TBL] [Abstract][Full Text] [Related]
10. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
12. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
14. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
[No Abstract] [Full Text] [Related]
15. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
Eap CB; Guentert TW; Schãublin-Loidl M; Stabl M; Koeb L; Powell K; Baumann P
Clin Pharmacol Ther; 1996 Mar; 59(3):322-31. PubMed ID: 8653995
[TBL] [Abstract][Full Text] [Related]
19. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics and density functional studies on the metabolic selectivity of antipsychotic thioridazine by cytochrome P450 2D6: Connection with crystallographic and metabolic results.
Sasahara K; Mashima A; Yoshida T; Chuman H
Bioorg Med Chem; 2015 Sep; 23(17):5459-65. PubMed ID: 26264841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
